DXCM Dexcom

Q2 2025 10-Q

Filed: Jul 30, 2025Period ending Jun 30, 2025

Health Care

Surgical & Medical Instruments & ApparatusSEC EDGAR

Dexcom (DXCM) 10-Q quarterly report for Q2 2025, filed with SEC EDGAR on Jul 30, 2025 for the fiscal period ending Jun 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q2 2025 10-Q

Management Discussion & Analysis

• Revenue $1.16B, up 15% YoY from $1.00B in Q2 2024, driven by disposable sensor volume growth
• Operating margin 18.4% vs 15.7% YoY, operating income $212.6M up 35% reflecting improved profitability

+3 more insights

Risk Factors

• No newly added risk factors this quarter; risk section supplements and supersedes 2024 10-K risks
• No material changes to previously disclosed risks; 10-K risk factors remain primary disclosures

+3 more insights

Quarterly Financial Summary
XBRL

Revenue

$1.2B

▲ +15.2% YoY▲ +11.7% QoQ

Net Income

$180M

▲ +25.3% YoY▲ +70.6% QoQ

Gross Margin

59.5%

▼ -287bp YoY▲ +267bp QoQ

Operating Margin

18.4%

▲ +264bp YoY▲ +547bp QoQ

Net Margin

15.5%

▲ +125bp YoY▲ +537bp QoQ

EPS (Diluted)

$0.44

▲ +25.7% YoY▲ +63.0% QoQ

Operating Cash Flow

$303M

▲ +8.4% YoY▲ +64.9% QoQ

Source: XBRL data from Dexcom Q2 2025 10-Q filing on SEC EDGAR. All figures in USD.

Other Dexcom Quarterly Reports

Q3 2025 10-Q

Get deeper insights on Dexcom

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.